Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles:
Related suggestion:
Hard right makes hay with European farmers' anger ahead of June electionsItaly starting Davis Cup title defense against Brazil and US plays ChileIsraeli soccer facing Palestinian calls for action by FIFA at annual congressChildren played just yards from where headless torso was found at nature reserve, police revealCost of privately renting homes rises by more than 9% in a yearSarah Paulson, 49, talks aging gracefully without Botox: 'I don't shoot anything into my face'Ethnic army intercepts junta offensive on ThaiSchwarber homers twice and Sánchez pitches 6 strong innings as Phillies finish sweep of RockiesUS tourists trapped in Dubai traumatized by floods swamping the desert playgroundRosie Huntington
2.5076s , 6498.1875 kb
Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,World Weaver news portal